MobiHealth News January 27, 2023
The funds will help the company grow its platform and scale partnerships with life science companies and healthcare systems.
Tech-enabled clinical trial platform Paradigm announced its launch alongside a $203 million Series A funding round co-led by ARCH Venture Partners and General Catalyst.
F-Prime Capital, LUX Capital, GV, Magnetic Ventures and Mubadala Capital also participated in the round. American Cancer Society’s BrightEdge fund was a strategic investor.
The company also announced its acquisition of Deep Lens, a patient recruitment platform for oncology-focused clinical trials.
Paradigm, conceived by ARCH Venture Partners and co-incubated by ARCH and General Catalyst, said it is building a platform that aims to streamline the clinical trial process for patients and connect biopharmaceutical trial sponsors...